基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

已收盘 11-22 16:08:13

1.960

-0.030

-1.51%

最高2.030	最低1.900	成交量165.89万
今开1.990	昨收1.990	日振幅6.53%
总市值25.17亿	流通市值25.17亿	总股本12.84亿
成交额329.27万	换手率0.13%	流通股本12.84亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":1.96,"timestamp":1732262893015,"preClose":1.99,"halted":0,"volume":1658921,"delay":0,"floatShares":1284207212,"shares":1284207212,"eps":-0.31198078,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.03,"latestTime":"11-22 16:08:13","open":1.99,"high":2.03,"low":1.9,"amount":3292733,"amplitude":0.065327,"askPrice":1.96,"askSize":58500,"bidPrice":1.93,"bidSize":237000,"shortable":0,"etf":0,"ttmEps":-0.11977222749848199,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"listingDate":1551110400000,"adjPreClose":1.99,"openAndCloseTimeList":[[1732239000000,1732248000000],[1732251600000,1732262400000]],"volumeRatio":1.313061,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"2485104559","title":"基石药业(02616)与Pharmalink达成商业化战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2485104559","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485104559?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:11","pubTimestamp":1732151463,"startTime":"0","endTime":"0","summary":"金吾财讯 | 基石药业(02616)宣布，公司与Pharmalink Store- L.L.C - O.P.C（“Pharmalink”）达成商业化战略合作。Pharmalink是一家总部设在阿拉伯联合酋长国的知名医药公司。根据许可及商业化协议，Pharmalink将获得舒格利单抗在中东和北非地区，包括沙乌地阿拉伯、阿拉伯联合酋长国、科威特、卡达、阿曼、巴林，阿尔及利亚、突尼斯、埃及、摩洛哥、利比亚，以及南非的商业化权利。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/Y2MwODZhYWZmNGQzMDgwOTQyYjU5NWM2YWIxYjEyMTA4MTkwNzMzNjk5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/Y2MwODZhYWZmNGQzMDgwOTQyYjU5NWM2YWIxYjEyMTA4MTkwNzMzNjk5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948120","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2485010437","title":"基石药业(02616.HK)向Pharmalink授予舒格利单抗中东和北非地区商业化权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2485010437","media":"阿斯达克财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485010437?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:04","pubTimestamp":1732151040,"startTime":"0","endTime":"0","summary":"基石药业公布，与阿联酋医药公司Pharmalink达成商业化战略合作。根据许可及商业化协议，Pharmalink将获得舒格利单抗在中东和北非地区，包括沙特阿拉伯、阿联酋、科威特、卡达、阿曼、巴林，阿尔及利亚、突尼斯、埃及、摩洛哥、利比亚，以及南非的商业化权利。据此，基石药业将从Pharmalink获得首付款及后续注册里程碑付款，以及舒格利单抗净销售额的特许权使用费，而Pharmalink将负责上述地区舒格利单抗注册及商业化相关活动。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190730155921777_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190730155921777_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1398359/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2485093551","title":"基石药业-B与Pharmalink就舒格利单抗在中东和非洲地区达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2485093551","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485093551?lang=zh_cn&edition=full","pubTime":"2024-11-21 08:29","pubTimestamp":1732148941,"startTime":"0","endTime":"0","summary":"格隆汇11月21日丨基石药业-B发布公告，公司与Pharmalink Store- L.L.C - O.P.C 达成商业化战略合作。Pharmalink是一家总部设在阿拉伯联合酋长国的知名医药公司。根据许可及商业化协议，Pharmalink将获得舒格利单抗在中东和北非地区，包括沙乌地阿拉伯、阿拉伯联合酋长国、科威特、卡达、阿曼、巴林，阿尔及利亚、突尼斯、埃及、摩洛哥、利比亚，以及南非的商业化权利。请读者仅作参考，并请自行承担全部责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121083134abd33a15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121083134abd33a15&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2485709105","title":"基石药业-B(02616)与Pharmalink就舒格利单抗在中东和非洲地区达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2485709105","media":"智通财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485709105?lang=zh_cn&edition=full","pubTime":"2024-11-21 08:15","pubTimestamp":1732148104,"startTime":"0","endTime":"0","summary":"Pharmalink是一家总部设在阿拉伯联合酋长国的知名医药公司。根据许可及商业化协议(协议)，Pharmalink将获得舒格利单抗在中东和北非地区，包括沙乌地阿拉伯、阿拉伯联合酋长国、科威特、卡达、阿曼、巴林，阿尔及利亚、突尼斯、埃及、摩洛哥、利比亚，以及南非的商业化权利。根据协议，基石药业将从Pharmalink获得首付款及后续注册里程碑付款，以及舒格利单抗净销售额的特许权使用费,而Pharmalink将负责上述地区舒格利单抗注册及商业化相关活动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2484016644","title":"基石药业-B11月20日遭主力抛售89万元 环比增加256.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484016644","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484016644?lang=zh_cn&edition=full","pubTime":"2024-11-20 16:17","pubTimestamp":1732090624,"startTime":"0","endTime":"0","summary":"11月20日, 基石药业-B股价涨1.53%，报收1.99元，成交金额281万元，换手率0.11%，振幅3.06%，量比0.95。基石药业-B今日主力资金净流出89万元，连续3日净流出，上一交易日主力净流出25万元，今日环比增加256.00%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为54.55%，平均跌幅为2.70%。该股近5个交易日上涨9.34%，主力资金累计净流出181万元；近20日主力资金累计净流出252万元，其中净流出天数为13日。该股主力净额占比0.03%，港股市场排名2569/2640。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120161746a247f718&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120161746a247f718&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2484515639","title":"基石药业-B(02616)上涨5.32%，报1.98元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484515639","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484515639?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:56","pubTimestamp":1731985012,"startTime":"0","endTime":"0","summary":"11月19日，基石药业-B(02616)盘中上涨5.32%，截至10:56，报1.98元/股，成交134.51万元。基石药业主要专注于抗肿瘤药物的研发，以满足中国和全球癌症患者的医疗需求，目前已经成功上市4款创新药，获批14项新药上市申请以及9项适应症，并且在研发管线中包括12款候选药物。公司具有一支全面覆盖药物发现、研发、生产和商业运营等关键环节的专业团队。截至2024年中报，基石药业-B营业总收入2.54亿元、净利润1569.9万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/19105645438422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2484954353","title":"基石药业-B盘中异动 股价大涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484954353","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484954353?lang=zh_cn&edition=full","pubTime":"2024-11-19 10:56","pubTimestamp":1731985004,"startTime":"0","endTime":"0","summary":"2024年11月19日早盘10时56分，基石药业-B股票出现异动，股价急速上涨5.32%。截至发稿，该股报1.980港元/股，成交量69.7万股，换手率0.05%，振幅7.45%。基石药业-B股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，康希诺生物、云顶新耀-B、基石药业-B涨幅较大，振幅较大的相关个股有晶泰科技、百奥赛图-B、腾盛博药-B，振幅分别为11.35%、9.67%、8.33%。基石药业-B公司简介：基石药业是一家中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111910564498e43672&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111910564498e43672&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2483910928","title":"基石药业－Ｂ(02616)出现大手买入90.85万股，成交价$1.81，涉资164.438万","url":"https://stock-news.laohu8.com/highlight/detail?id=2483910928","media":"阿斯达克财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483910928?lang=zh_cn&edition=full","pubTime":"2024-11-14 11:30","pubTimestamp":1731555000,"startTime":"0","endTime":"0","summary":"[大手成交]基石药业－Ｂ(02616)在上午11:30出现大手买入，成交量为90.85万，成交价为港币$1.81，涉资164.438万。至目前为止，股价跌2.198%，今日最高价为$1.84，而最低价为$1.76，总成交量为146.55万股，总成交金额港币$264.701万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2411147501/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2483496830","title":"基石药业-B(02616)下跌5.73%，报1.81元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483496830","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483496830?lang=zh_cn&edition=full","pubTime":"2024-11-13 13:44","pubTimestamp":1731476665,"startTime":"0","endTime":"0","summary":"11月13日，基石药业-B(02616)盘中下跌5.73%，截至13:44，报1.81元/股，成交149.19万元。基石药业主要专注于抗肿瘤药物的研发，以满足中国和全球癌症患者的医疗需求，目前已经成功上市4款创新药，获批14项新药上市申请以及9项适应症，并且在研发管线中包括12款候选药物。公司具有一支全面覆盖药物发现、研发、生产和商业运营等关键环节的专业团队。截至2024年中报，基石药业-B营业总收入2.54亿元、净利润1569.9万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13134445237798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2483418370","title":"基石药业-B盘中异动 下午盘股价大跌5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483418370","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483418370?lang=zh_cn&edition=full","pubTime":"2024-11-13 13:44","pubTimestamp":1731476663,"startTime":"0","endTime":"0","summary":"2024年11月13日下午盘13时44分，基石药业-B股票出现波动，股价急速下挫5.73%。截至发稿，该股报1.810港元/股，成交量80.65万股，换手率0.06%，振幅5.73%。基石药业-B股票所在的生物技术行业中，整体跌幅为2.13%。其相关个股中，正大企业国际、腾盛博药-B、贝康医疗-B涨幅较大，振幅较大的相关个股有宜明昂科-B、正大企业国际、科济药业-B，振幅分别为23.63%、20.75%、14.29%。基石药业-B公司简介：基石药业是一家中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113134423971a6346&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113134423971a6346&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2482723171","title":"国内三抗药物研发开始涌现，基石药业、维立志博等药企披露新动态","url":"https://stock-news.laohu8.com/highlight/detail?id=2482723171","media":"中国制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482723171?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:12","pubTimestamp":1731395557,"startTime":"0","endTime":"0","summary":"截至目前，全球暂无三特异性抗体获批上市。但是当前也有一批国内药企正在积极布局三特异性抗体，并且日益获得新突破。据悉，双方将基于维立志博的CD19xBCMAxCD3三特异性T细胞衔接器抗体LBL-051，成立新药研发公司Oblenio Bio，共同推进LBL-051进入临床研究。此外，根据梳理， 三生制药 、嘉和生物、 华东医药 、百利药业、 泽璟制药 等国内药企，也在通过自主研发或授权引进等方式布局三特异性抗体。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112151802abb8f360&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112151802abb8f360&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2482712102","title":"基石药业-B11月11日主力资金流出18万元 连续7日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2482712102","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482712102?lang=zh_cn&edition=full","pubTime":"2024-11-11 16:15","pubTimestamp":1731312952,"startTime":"0","endTime":"0","summary":"11月11日, 基石药业-B股价涨1.02%，报收1.98元，成交金额480万元，换手率0.19%，振幅5.10%，量比0.91。基石药业-B今日主力资金净流出18万元，连续7日净流出，上一交易日主力净流出24万元，今日环比减少25.00%。该股近5个交易日下跌3.90%，主力资金累计净流出246万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入191万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111161614abb55b86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111161614abb55b86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2482124005","title":"基石药业(02616)公布CS2009临床前研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2482124005","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482124005?lang=zh_cn&edition=full","pubTime":"2024-11-11 12:18","pubTimestamp":1731298685,"startTime":"0","endTime":"0","summary":"金吾财讯 | 基石药业 公布，公司在第39届癌症免疫治疗学会年会上公布管线2.0重磅产品CS2009的临床前数据。CS2009是一款靶向PD-1、CTLA-4及VEGFA的三特异性抗体。2)临床前数据显示，CS2009具有明显优于潜在竞品的抗肿瘤活性。3)CS2009有望覆盖广泛瘤种、成为同类首创/同类最优的下一代肿瘤免疫骨架产品。4)基石药业计划于2024年底或2025年初提交CS2009的临床研究用新药申请，并在2025年初开展首次人体研究。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/YWMzMDYxNjliM2VjNmQwMDUwODkzNDE4MTMw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/YWMzMDYxNjliM2VjNmQwMDUwODkzNDE4MTMw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947457","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2482247974","title":"基石药业-B(02616)在第39届癌症免疫治疗学会年会上公布管线2.0重磅产品CS2009的临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2482247974","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482247974?lang=zh_cn&edition=full","pubTime":"2024-11-11 12:03","pubTimestamp":1731297800,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司在第39届癌症免疫治疗学会年会上公布管线2.0重磅产品CS2009的临床前数据。CS2009是一款靶向PD-1、CTLA-4及 VEGFA的三特异性抗体。其疾病覆盖范围广泛，包括非小细胞肺癌、卵巢癌、肾细胞癌、宫颈癌、肝细胞癌、胃癌等。CS2009目前正处于IND申请准备流程中，预计于2024年底或2025年初提交IND申请、2025年初正式进入首次人体研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02616"],"gpt_icon":0},{"id":"2481252929","title":"基石药业-B11月07日遭主力抛售112万元 环比增加194.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481252929","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481252929?lang=zh_cn&edition=full","pubTime":"2024-11-07 16:15","pubTimestamp":1730967342,"startTime":"0","endTime":"0","summary":"11月07日, 基石药业-B股价跌1.48%，报收2.00元，成交金额627万元，换手率0.25%，振幅7.39%，量比0.95。基石药业-B今日主力资金净流出112万元，连续5日净流出，上一交易日主力净流出38万元，今日环比增加194.74%。近一年数据显示，该股主力连续5日净流出后，次日下跌概率为66.67%，平均跌幅为1.58%。该股近5个交易日下跌6.98%，主力资金累计净流出297万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入257万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107161602aba94d99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107161602aba94d99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2481946678","title":"基石药业-B盘中异动 下午盘股价大跌5.91%报1.910港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481946678","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481946678?lang=zh_cn&edition=full","pubTime":"2024-11-07 13:36","pubTimestamp":1730957767,"startTime":"0","endTime":"0","summary":"2024年11月07日下午盘13时36分，基石药业-B股票出现波动，股价大幅跳水5.91%。截至发稿，该股报1.910港元/股，成交量162.15万股，换手率0.13%，振幅3.94%。资金方面，该股资金流入41.8115万港元，流出251.169万港元。基石药业-B股票所在的生物技术行业中，整体跌幅为0.46%。其相关个股中，科济药业-B、正大企业国际、药明合联涨幅较大，振幅较大的相关个股有科济药业-B、百奥赛图-B、北海康成-B，振幅分别为45.67%、17.38%、17.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107133607a21f15ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107133607a21f15ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2481994090","title":"医药股普遍下行 金斯瑞生物科技(01548)跌超3% 第十批国采药品目录官宣 机构料续淘汰力度将加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2481994090","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481994090?lang=zh_cn&edition=full","pubTime":"2024-11-07 09:54","pubTimestamp":1730944476,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股普遍下行，荣昌生物 跌4.09%，药明巨诺、金斯瑞生物科技跌超3%，基石药业、百济神州跌逾2%，和黄医药跌1.55%，先声药业跌1.47%，康方生物跌1.19%，云顶新耀跌1.08%。2024年国家医保药品目录调整现场谈判已结束，新目录预计11月底公布，明年1月1日正式实施，涉及127家企业162种药品。此次国采品种数量和入围门槛均为历史之最，预计后续淘汰力度将加大，注射剂比例创新高，将改变相关药企的竞争格局。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947254","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU0348784397.USD","HK0000320223.HKD","LU1794554557.SGD","LU2328871848.SGD","02096","LU1969619763.USD","IE00BPRC5H50.USD","01952","BK1191","BK1576","LU0417516571.SGD","BK1161","LU1720050803.USD","00013","HK0000320264.USD","09939","BK1141","HK0000306701.USD","LU2488822045.USD","BK1587","IE00B543WZ88.USD","01548","159938","02126","LU0348783233.USD","BK1583","BK1500","02616","09995","BK1515","09926","06160","BK1574","BK1588","LU0588546209.SGD","HK0000306685.HKD","LU0307460666.USD"],"gpt_icon":0},{"id":"2481776691","title":"基石药业-B盘中异动 大幅上涨6.63%报2.090港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481776691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481776691?lang=zh_cn&edition=full","pubTime":"2024-11-06 10:19","pubTimestamp":1730859548,"startTime":"0","endTime":"0","summary":"2024年11月06日早盘10时19分，基石药业-B股票出现波动，股价快速拉升6.63%。截至发稿，该股报2.090港元/股，成交量22.15万股，换手率0.02%，振幅6.63%。资金方面，该股资金流入25.132万港元，流出15.159万港元。基石药业-B股票所在的生物技术行业中，整体涨幅为0.29%。其相关个股中，华康生物医学、来凯医药-B、荃信生物-B涨幅较大，振幅较大的相关个股有来凯医药-B、华康生物医学、科济药业-B，振幅分别为12.52%、9.34%、9.19%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106101908aba3abe1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106101908aba3abe1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2481660602","title":"基石药业(02616.HK)将于美国ASH年会披露治疗淋巴瘤药物CS5001临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2481660602","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481660602?lang=zh_cn&edition=full","pubTime":"2024-11-06 08:50","pubTimestamp":1730854200,"startTime":"0","endTime":"0","summary":"基石药业公布，将在第66届美国血液学会年会上公布管线2.0重磅产品CS5001 针对淋巴瘤的最新临床数据。ASH年会将于12月7至10日在美国加利福尼亚州圣地亚哥及线上举行。公司将在此次ASH年会公布CS5001首次人体研究中针对晚期B-细胞淋巴瘤的最新安全性和有效性数据。从初始起效剂量起，CS5001针对晚期霍奇金淋巴瘤的ORR达60%，非霍奇金淋巴瘤的ORR达50%。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190730155921777_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190730155921777_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1394420/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2481266122","title":"基石药业-B(02616)将在第66届美国血液学会(ASH)年会上公布 CS5001针对淋巴瘤的最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2481266122","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481266122?lang=zh_cn&edition=full","pubTime":"2024-11-06 08:03","pubTimestamp":1730851408,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，该公司将在第66届美国血液学会年会上公布管线2.0重磅产品CS5001针对淋巴瘤的最新临床数据。根据本公司在 2024年美国临床肿瘤学会年会上公布其首次人体研究的初步数据，CS5001在不同剂量水平、对于多线经治的晚期实体瘤和淋巴瘤均能表现出良好的耐受性和令人鼓舞的抗肿瘤活性。本公司将在此次ASH年会公布CS5001首次人体研究中针对晚期B-细胞淋巴瘤的最新安全性和有效性数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4109","BK1161","BK1574","ASH","LU2463526074.USD","02616"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":0.0994},{"period":"1month","weight":0.1056},{"period":"3month","weight":0.5547},{"period":"6month","weight":0.5308},{"period":"1year","weight":-0.1911},{"period":"ytd","weight":-0.1233}],"compareEarnings":[{"period":"1week","weight":0.0085},{"period":"1month","weight":-0.0438},{"period":"3month","weight":0.1129},{"period":"6month","weight":0.0533},{"period":"1year","weight":0.1052},{"period":"ytd","weight":0.1498}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家中国投资控股公司。该公司通过子公司主要从事生物制药产品的研发、生产和销售业务。该公司主要产品是肿瘤免疫治疗疗法和分子靶向药物。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.078236},{"month":2,"riseRate":0.2,"avgChangeRate":-0.045216},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.116412},{"month":4,"riseRate":0.2,"avgChangeRate":-0.028106},{"month":5,"riseRate":0.4,"avgChangeRate":0.039766},{"month":6,"riseRate":0.666667,"avgChangeRate":0.097121},{"month":7,"riseRate":0.5,"avgChangeRate":-0.049356},{"month":8,"riseRate":0.333333,"avgChangeRate":0.010588},{"month":9,"riseRate":0.5,"avgChangeRate":-0.033892},{"month":10,"riseRate":0.5,"avgChangeRate":0.015157},{"month":11,"riseRate":0.666667,"avgChangeRate":0.004495},{"month":12,"riseRate":0.4,"avgChangeRate":0.018876}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}